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Abstract
Background: The Wnt signaling pathway is activated by mutations in the APC and β-catenin genes
in many types of human cancer. β-catenin is stabilized by these mutations and activates
transcription in part by acting as a bridge between Tcf/LEF proteins and the HD2 domain of the
BCL9 coactivator. We have previously described oncolytic adenoviruses with binding sites for Tcf/
LEF transcription factors inserted into the early viral promoters. These viruses replicate selectively
in cells with activation of the Wnt pathway. To increase the activity of these viruses we have fused
the viral transactivator E1A to the BCL9 HD2 domain.
Methods: Luciferase assays, co-immunoprecipitation and Western blotting, immunofluorescent
cell staining and cytopathic effect assays were used to characterize the E1A-HD2 fusion protein and
virus in vitro. Growth curves of subcutaneous SW620 colon cancer xenografts were used to
characterize the virus in vivo.
Results: The E1A-HD2 fusion protein binds to β-catenin in vivo and activates a Tcf-regulated
luciferase reporter better than wild-type E1A in cells with activated Wnt signaling. Expression of
the E1A-HD2 protein promotes nuclear import of β-catenin, mediated by the strong nuclear
localization signal in E1A. Tcf-regulated viruses expressing the fusion protein show increased
expression of viral proteins and a five-fold increase in cytopathic effect (CPE) in colorectal cancer
cell lines. There was no change in viral protein expression or CPE in HeLa cells, indicating that E1A-
HD2 viruses retain selectivity for cells with activation of the Wnt signaling pathway. Despite
increasing the cytopathic effect of the virus in vitro, fusion of the HD2 domain to E1A did not
increase the burst size of the virus in vitro or the anti-tumor effect of the virus in an SW620
xenograft model in vivo.
Conclusion: Despite an increase in the nuclear pool of β-catenin, the effects on viral activity in
colon cancer cells were small, suggesting that factors acting downstream of β-catenin are limiting
for viral replication and toxicity in these cells. The approach of fusing E1A to a protein domain
implicated in oncogenic signaling could be used to selectively increase the activity of oncolytic
viruses targeting several other pathways defective in cancer.
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Background
The Wnt signaling pathway is pathologically activated in
many different types of human cancer [1]. Mutations in
either the APC or β-catenin genes are seen in about 90%
of human colorectal cancers [1]. Most APC mutations
truncate the protein N-terminal to the axin binding
domain. This prevents the assembly of the multiprotein
complex that normally phosphorylates the N-terminus of
β-catenin in the absence of Wnt ligand [2]. In hereditary
non-polyposis colon cancer (HNPCC), APC is wild type
but β-catenin is mutated in its N-terminal phosphoryla-
tion sites. When phosphorylated on these sites β-catenin
is targeted for proteasomal degradation by the β-TRCP
ubiquitin ligase [3]. Unphosphorylated β-catenin is stable
and translocates to the nucleus, where it binds to mem-
bers of the Tcf/Lef family of transcription factors and
recruits coactivators such as p300, BCL9 and pygopus to
activate transcription of Wnt target genes [4-7]. BCL9 is
the human homolog of the Drosophila legless gene. A
protein containing only the HD2 domain of BCL9 and the
NHD domain of pygopus is able to rescue the embryonic
phenotype of legless and pygopus mutant flies [4]. Since
the HD2 domain binds to β-catenin, this suggests that the
main function of BCL9 is to act as an adaptor that brings
together β-catenin and pygopus.
During an adenoviral infection, E1A is the first gene to be
expressed by the virus. Two main spliced forms are pro-
duced, 12S and 13S, which encode proteins differing in
the presence of a zinc finger domain (Conserved Region 3,
CR3) that supplies the major transcription activation
function in E1A. The CR3 domain binds to ATF proteins,
transcription factors that bind to cognate sites in the early
viral promoters, and to the Sur2 subunit of the Mediator
complex [8-10]. We have previously described replicating
adenoviruses with Tcf sites in the early promoters [11,12].
These viruses replicate selectively in cells with activation
of the Wnt signaling pathway, including many colorectal
cancer cells. Since the Tcf sites replace the ATF sites in the
viral promoters, the transactivation function of E1A is
entirely replaced by Tcf-dependent coactivator functions
in these viruses. In some colorectal cancer cell lines, the
level of Tcf-dependent transactivation is insufficient to
achieve wild type virus replication [12]. To circumvent
this problem, we have fused E1A to the BCL9 HD2
domain in a Tcf-regulated virus. We show that E1A-HD2
proteins are able to bind to β-catenin and can activate
transcription from Tcf-regulated promoters better than
wild type E1A. Despite showing five-fold more activity in
cytopathic effect assays in vitro, the activity of the virus
was unchanged in xenografts of SW620 colon cancer cells
in vivo.
Methods
E1A-HD2 mutagenesis
To create an E1A-HD2 fusion gene, an XmaI restriction
site was inserted at the C-terminus of the E1A 12S coding
sequence by PCR with the primers CGGGCCT-
GGGGCGTTTACAG (oCF83) and GGTAAGGTGTAAAC-
CTGTGAT TGC (oCF84) to give the plasmid pALP3. The
HD2 sequence was amplified from the BCL9 cDNA with
the primers TACCCGGGAGCAATAGCTCTTCAG (oCF85)
and ACCCCGGGATTCTGCTGCGGTCCCCCAC (oCF86).
The product was cut with XmaI (underlined) and inserted
into the XmaI site of pALP3 to give pALP5. The E1A 12S-
HD2 sequence was back-cloned into pCF9 [12] with HpaI
and BamHI to give pALP9, a pCDNA3 vector expressing
the E1A 12S-HD2 fusion protein. The E1A-HD2 sequence
was transferred from pALP5 into pALP2 (E1A 13S in a
pUC19-based vector) with PshAI and NdeI to create
pALP7. The E1A 13S-HD2 sequence was back-cloned into
pCF113 (E1A 13S in pCDNA3) to give pALP8, a pCDNA3
vector expressing the E1A 13S-HD2 fusion protein.
Adenovirus mutagenesis
The parental virus is adenovirus 5 (ATCC VR5). The Hin-
dIII/EcoRI fragment of pUC19 was inserted into pCDNA3
to give pCF357. The region containing the Tcf-E1A and
the Tcf-E1B promoters was isolated from vpCF2 [the YAC-
BAC used to create vCF22, ref [12]] with KpnI and SpeI
and inserted into pCF357 to create pCF358. The SphI frag-
ment of pCF358 was inserted into pCF34 [12] to give
pCF389. The region encompassing the C-terminus of E1A
fused to the HD2 domain of BCL-9 was isolated from
pALP8 with BsmBI and HpaI and cloned into pCF358 to
create pCF387. This was cut by KpnI and XhoI and
inserted into pCF389 to give pCF393. The gap repair vec-
tor was created by transferring the PacI fragment of
pCF393 into pCF1 [12] to give pCF398. This plasmid con-
tains the right and left ends of the virus separated by a SalI
site. The Tcf-HD2 viral genomic plasmids (vpCF19 and
vpCF21) were created by gap repair of pCF398 with
genomic DNA from vKH1 and vCF22, respectively [12-
14]. vpCF19 and vpCF21 were cut with PacI and con-
verted into the viruses vCF192 and vCF212 using cR1 cells
for the initial transfection and SW480 cells for the subse-
quent amplification and plaque purification. After expan-
sion on SW480, the viruses were purified by CsCl banding
and size exclusion chromatography (Microspin S400HR
columns, Amersham, Little Chalfont, UK). Virus was
stored at -70°C in 1 M NaCl, 100 mM Tris-HCl pH 8.0
and 10% glycerol. Virus was titered on SW480 cells and
scored at 10 days. The particle to pfu ratios were: vKH1 36,
vCF192 30, vCF22 50, vCF212 33.
Cell lines
SW480 (ATCC CCL-228), SW620 (ATCC CCL-227),
HCT116 (CCL-247) and HT29 (HTB-38) were suppliedBMC Cancer 2006, 6:236 http://www.biomedcentral.com/1471-2407/6/236
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by ATCC. ISREC-O1 [15] and Co115 cells [16] were pro-
vided by Dr B Sordat. Her911 [17] and HeLa cells were
provided by Dr P Beard and Dr D Lane, respectively. cR1
cells are C7 cells expressing myc-tagged ∆N-β-catenin
[12]. Cell lines were grown in Dulbecco's modified Eagle's
medium (DMEM) with 10% fetal calf serum (Invitrogen,
Carlsbad, CA).
Luciferase assays
The E2 reporters were described by Brunori et al [11]. They
contain a minimal adenoviral E2 promoter controlled by
four Tcf sites (the same promoter as is present in the
vCF22 virus). Cells were seeded at 2.5 × 105 cells per 35-
mm well 24 h before transfection. 100 ng of reporter plas-
mid and 500 ng of the vector expressing the E1A proteins
or ∆N-β-catenin were used per well, and pCDNA3 empty
vector was added to adjust the total amount of DNA to 1.1
µg. The DNA was incubated for 20 min with 3 µl of Lipo-
fectamine 2000 (Invitrogen) prior to addition to cells.
Cells were harvested 48 h after transfection and luciferase
reporter assays were performed according to the manufac-
turer's instructions (Promega, Madison, WI) using a Bio-
counter (Lumac, Landgraaf, The Netherlands). Error bars
are SD.
Western blotting
Cells were infected with 10 plaque-forming units (pfu)
per cell and harvested 24 h later in SDS-PAGE sample
buffer. E1A, β-catenin, DBP, Fiber and pRb were detected
with the M58 (BD Biosciences, San Diego, CA), C2206
(Sigma-Aldrich, Buchs, Switzerland), B6 [18], 4D2
(Research Diagnostics, Flanders, NJ) and C-15 (Santa
Cruz Biotechnology, Santa Cruz, CA) antibodies, respec-
tively. E4orf6 and E4orf6/7 were detected with the RSA3
antibody [19].
Cytopathic effect and MTT assays
For CPE assays, cells in six-well plates were infected with
10-fold dilutions of virus. After 6 to 9 days, the cells were
fixed with 4% formaldehyde in PBS and stained with crys-
tal violet. For MTT assays, cells in 96-well plates were
infected with 3.3-fold dilutions of virus. After 5 to 8 days,
10 µl of 5 mg/ml MTT (thiazolyl blue 98%, Sigma) was
added to the medium for 3 hours. The medium was
removed and the wells were dried at 37°C for 30 minutes.
100 µl of isopropanol was added to each well and the
plates were shaken for 30 minutes. The absorbance was
read at 562 nm on a Multiskan Ascent microplate pho-
tometer (Thermo Electron corp., Waltham, MA). Error
bars are SD.
Burst assays
Cells were infected with 1 pfu/cell. Medium was replaced
4 hours later. Cells were harvested 48 hours after infec-
tion, freeze-thawed three times and the titer was measured
on HER911 cells stably expressing a Lef1-VP16 fusion pro-
tein. Error bars are SEM.
Immunofluorescence
Cells were infected with 10 pfu/cell. 24 hours later, the
wells were washed twice with PBS and the cells were fixed
with 200 µl of formaldehyde 4% in PBS for 15 min. Cells
were washed once with PBS and permeabilized with 0.1%
Triton X-100, 1% BSA in PBS for 10 min. Cells were
washed three times with PBS and blocked with 5% BSA,
5% FCS in PBS for 30 min. Cells were washed once with
PBS and incubated with 200 µl of rabbit anti β-catenin
antibody (100 µg/ml, C2206, Sigma) or mouse anti E1A
antibody (2 µg/ml, M58, BD Biosciences) in 0.5% BSA,
0.5% FCS in DMEM (staining buffer) at 37°C for 90 min.
Cells were washed three times with PBS and incubated
with 200 µl of Alexa488-conjugated goat anti-mouse (20
µg/ml, a-11029, Molecular Probes, Eugene, OR) or Cy3-
coupled donkey anti-rabbit (2 µg/ml, 711-165-152, Jack-
son Immunoresearch, West Grove, PA) secondary anti-
bodies in staining buffer for 30 min at 37°C. Cells were
washed three times with PBS. Pictures were taken with an
LSM510 confocal microscope (Zeiss, Oberkochen, Ger-
many).
Immunoprecipitation
Cells were infected with 10 pfu/cell. 24 hours later, the
cells were washed three times with ice-cold PBS pH 8.1
and lysed in 1 ml of 0.1% NP-40 buffer containing pro-
tease inhibitors. The cell extracts were collected, incubated
at 4°C for 15 min and centrifuged at 13,000 rpm for 15
min at 4°C. The supernatant was collected and the protein
content was measured by BCA assay (Pierce Biotechnol-
ogy, Rockford, IL). One mg of total protein extract was
diluted in 1 ml with PBS pH 8.1 + 0.1% BSA (solution A)
and pre-cleared for 2 hours at 4°C on 100 µl of washed
Dynabeads (Dynal Biotech, Oslo, Norway). One ml of a
solution containing 5 µg of mouse anti-E1A antibody
(M58, BD Biosciences) in solution A was incubated with
washed Dynabeads. After 8 hours at 4°C, the supernatant
was removed and the beads were washed three times with
solution A. The pre-cleared lysate was incubated with the
antibody-coupled beads overnight at 4°C, washed three
times in NP-40 lysis buffer and extracted with 60 µl of
SDS-PAGE sample buffer.
Xenograft experiments
Four week old female NMRI nu/nu mice were purchased
from Elevage Janvier (Le Genest St Isle, France). Subcuta-
neous SW620 flank xenografts were made by injecting 107
cells. Mice (six per group) were injected with virus when
tumors reached 80–150 mm3 in size. A total of 1 × 1011
particles were injected into the tail vein, given as one shot
of 1 × 1010 then three shots of 3 × 1010 particles at four
hour intervals on day 0. This fractionated schedule wasBMC Cancer 2006, 6:236 http://www.biomedcentral.com/1471-2407/6/236
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used to decrease side effects and prolong the half-life of
the virus in the circulation [14]. Tumor size was measured
every two days. Tumor volume was calculated according
to the formula, volume = length × width2 × 3.14/6. Error
bars are SEM.
Results
E1A-HD2 transactivates Tcf-regulated promoters
We reasoned that fusion of the HD2 domain of BCL9 to
E1A should lead to recruitment of E1A to Tcf-regulated
promoters in cells containing stabilized β-catenin (Figure
1A). In the absence of Wnt ligand or activating mutations
in the pathway, β-catenin is rapidly degraded and should
be unable to recruit the fusion protein to the Tcf sites in
the promoter. The HD2 domain was fused to both 12S
and 13S E1A cDNAs in order to assess the contribution of
the E1A CR3 domain (Figure 1B). Luciferase assays were
performed using a Tcf-E2 promoter reporter [11] in
SW480 cells, which have an APC mutation that activates
the Wnt signaling pathway, and in HeLa cells, which lack
Wnt pathway activation. As shown previously, 12S E1A
repressed the promoter in SW480 cells, probably because
of p300 sequestration by E1A [12]. Fusion of HD2 to 12S
relieved this repression (Figure 1C). The 13S E1A protein
alone had little effect, and the 13S-HD2 fusion protein
activated the promoter 2.5-fold (Figure 1C). In HeLa cells,
the Tcf-E2 promoter had low activity which was not
affected by E1A or the fusion proteins. Cotransfection of a
stabilized form of β-catenin (∆N-β-catenin) weakly acti-
vated the promoter. This β-catenin-dependent activity was
decreased by 12S E1A and increased by 12S-HD2 (Figure
1D). Cotransfection of ∆N-β-catenin and 13S E1A acti-
vated the reporter to a similar level as 12S-HD2, whereas
cotransfection of ∆N-β-catenin and 13S-HD2 strongly
activated the promoter (Figure 1D). Taken together, these
results show that addition of the HD2 domain to E1A
relieves the repression of β-catenin-dependent transcrip-
tion by 12S E1A and stimulates the activation of β-cat-
enin-dependent transcription by 13S E1A.
E1A-HD2 binds to and promotes nuclear localization of β-
catenin
To test the role of the E1A-HD2 fusion protein during viral
infection, we inserted the E1A-HD2 gene into an oncolytic
adenovirus (serotype 5) with Tcf-binding sites in the E1A,
E1B, E2 and E4 promoters and deletion of the NF1, NFκB
and AP1 sites in the E3 promoter [12] (Figure 2A). Co-
immunoprecipitation experiments were performed to
determine whether E1A-HD2 fusion proteins are able to
bind to β-catenin in SW480 and HT29 cells, in which β-
catenin is stabilized by mutations in APC. The cells were
either mock infected or infected with the parental or E1A-
HD2 viruses. Immunoblotting of cell lysates showed that
E1A migrates as a larger protein after fusion to HD2. Mul-
tiple bands were seen, consistent with splicing of E1A into
different isoforms including 12S and 13S (Figure 2B). Cell
lysates were immunoprecipitated with an antibody
against E1A and immunoblotted for β-catenin and pRb.
pRb, which binds to the CR2 domain of E1A [20], was
used as a positive control for the immunoprecipitation. β-
catenin was co-precipitated by the E1A-HD2 fusion pro-
teins but not by wild-type E1A proteins (Figure 2B), con-
firming the previous report mapping the β-catenin
binding site in BCL9 to the HD2 domain [4].
To test the effect of the fusion protein on β-catenin local-
ization, SW480 cells were infected with the parental and
E1A-HD2 viruses. E1A has a strong nuclear localization
signal (NLS) [21], and its nuclear localization was not
altered by fusion to the HD2 domain (Figure 3G &3K). In
SW480 cells, β-catenin is found at multiple sites, includ-
ing the adherens junctions, cytoplasm and nucleus [Figure
3A, and ref [22]]. The localization of the protein remained
unchanged when the cells were infected with the parental
Tcf-regulated adenovirus (Figure 3E) but the nuclear pool
of  β-catenin was substantially enriched upon infection
with the E1A-HD2 virus (Figure 3I). Negative controls
confirmed that the E1A and β-catenin antibodies were
specific (Figure 3C, mock infection; Figure 3M, no pri-
mary β-catenin antibody). We conclude that the E1A-HD2
protein binds to β-catenin and translocates β-catenin to
the nucleus.
E1A-HD2 expression increases viral protein expression and 
cytopathic effect
To determine whether the E1A-HD2 protein increases the
activity of the Tcf-regulated promoters in the virus, lysates
of cells infected with the parental and E1A-HD2 viruses
were immunoblotted for DBP and E1A 24 hours after
infection. DBP is expressed from the E2 promoter, which
contains four Tcf sites in both viruses. Four colorectal can-
cer cell lines with an activated Wnt signaling pathway
(Hct116, HT29, ISREC-O1 and SW480) and one Wnt-neg-
ative cell line (HeLa) were tested. There was little effect on
E1A level but a reproducible increase in the expression of
DBP in all of the colon cancer cell lines infected with the
E1A-HD2 virus (Figure 4A). Viral protein expression was
examined in more detail in HT29 cells, which have the
lowest Tcf activity of the colon cancer cell lines tested [23].
At 24 hours post infection, weak DBP and E4 protein
expression were detectable, but only with the E1A-HD2
virus (Figure 4B). At 48 hours, E1A, DBP and E4 proteins
were all clearly expressed at higher levels by the E1A-HD2
virus. Late protein expression, measured by immunoblot-
ting for the fiber protein, was also higher at 48 hours,
reflecting increased viral replication (Figure 4B).
Cytopathic effect (CPE) assays were performed to deter-
mine whether increased viral protein expression led to
enhanced cell killing (Figure 5A). In HeLa and Hct116BMC Cancer 2006, 6:236 http://www.biomedcentral.com/1471-2407/6/236
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cells, the cytopathic effect of the virus was unchanged by
the presence of the HD2 domain. Since the fusion protein
is able to bind to β-catenin (data not shown), the lack of
effect in Hct116 suggests that factors downstream of pro-
moter activation are limiting in this colon cancer cell line.
All of the remaining cell lines showed an increase in cyto-
Transcription activation by E1A-HD2 fusion proteins Figure 1
Transcription activation by E1A-HD2 fusion proteins. A. Diagram showing the proteins that recruit the E1A-HD2 
fusion protein to Tcf sites. B. Diagram showing the fusion proteins used in the reporter assay. CR1-4: E1A conserved regions 1 
to 4 [39] C. Luciferase assays in SW480 cells transfected with a Tcf-E2 reporter and E1A expression vectors. D. Luciferase 
assays in HeLa cells transfected with a Tcf-E2 reporter and vectors expressing E1A and N-β-catenin. The activity is expressed 
in arbitrary units relative to the reporter alone in C, and the reporter plus N-β-catenin in D.
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β-catenin binds to the E1A-HD2 fusion protein in vitro Figure 2
β-catenin binds to the E1A-HD2 fusion protein in vitro. A. Diagram showing the viruses used in this study. Open circles 
represent four Tcf binding sites in the viral promoters. B. Co-precipitation of β-catenin through the HD2 domain. HT29 and 
SW480 cells were infected with the parental and E1A-HD2 viruses. E1A immunoprecipitates were immunoblotted for β-cat-
enin, pRb and E1A. Asterisks indicate immunoglobulin light and heavy chains.
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pathic effect (Figure 5A). MTT cell viability assays were
performed to provide a quantitative measure of the
increase in CPE. In HeLa and Hct116 cells, both viruses
showed equivalent cell killing, whereas the E1A-HD2
virus was more toxic than the parental virus in the remain-
ing cell lines (Figure 5B). The EC50 decreased five-fold in
these cell lines (Figure 5C). In conclusion, the Tcf-regu-
lated promoters were more active in colon cancer cells
infected with the E1A-HD2 virus, and in most cases this
resulted in a five-fold increase in cytopathic effect.
E1A-HD2 expression promotes nuclear localization of β-catenin Figure 3
E1A-HD2 expression promotes nuclear localization of β-catenin. SW480 cells were mock infected (A-D), infected 
with the parental virus (E-H), or infected with the E1A-HD2 virus (I-L), and stained for β-catenin (A, E, I) or E1A (C, G, K). 
DAPI staining was used to identify the nuclei (B, D, F, H, J, L). The primary antibody was omitted in M to verify the specificity 
of the secondary antibody used to detect β-catenin.
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E1A-HD2 does not increase anti-tumor efficacy in SW620 
xenografts
To test whether the increased pool of nuclear β-catenin
and CPE translate into an increase in efficacy in vivo, we
created a simpler version of the virus in which the E2 pro-
moter is wild type (vCF192). The reason for making this
choice was that the E2 promoter is the most sensitive to
the level of Tcf activity in the cell. Only the E1A, E1B and
E4 promoters contain Tcf sites. The vCF192 virus is iden-
tical to vKH1 [14] apart from the presence of the E1A-
HD2 fusion gene. The burst size of all the viruses was
tested on three colon cancer cell lines and HeLa cells (Fig-
ure 6A). There were only minimal differences between the
parental viruses (vCF22 and vKH1) and the E1A-HD2
derivatives (vCF212 and vCF192). The in vivo activity of
vCF192 was compared with that of vKH1 after intrave-
nous administration of 1 × 1011 particles of virus to mice
with subcutaneous SW620 xenografts. SW620 colon can-
cer cells are derived from the same tumor as SW480 cells,
and have similar high Tcf activity. We previously charac-
terized this model and showed that virus alone delays
tumor growth by about 10 days [14]. The E1A-HD2 virus
(vCF192) was indistinguishable from the parental virus in
this model (Figure 6B). We conclude that the small
increase in cytopathic effect seen in vitro does not sub-
stantially increase the activity of the virus in cells with
high Tcf activity in vivo.
Discussion
The main conclusion from this study is that fusion of E1A
to the BCL9 HD2 domain increases the activity of Tcf-reg-
ulated oncolytic adenoviruses in most colon cancer cell
The E1A-HD2 virus gives increased expression of viral proteins Figure 4
The E1A-HD2 virus gives increased expression of viral proteins. A. Western blot of extracts of the indicated cell lines 
probed for E1A and DBP (DNA Binding Protein, an E2 gene product) 24 hours after infection with the parental and E1A-HD2 
viruses. B. Western blot of HT29 extracts probed for E1A, DBP, E4orf6, E4orf6/7 and fiber at 24 and 48 hours after infection 
with the parental and E1A-HD2 viruses.
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The E1A-HD2 virus shows increased toxicity on cells with activated Wnt signaling Figure 5
The E1A-HD2 virus shows increased toxicity on cells with activated Wnt signaling. A. CPE assays. Cells were 
infected with 10-fold dilutions of virus starting from 100 pfu/cell in HeLa, Hct116 and HT29 cells, and starting from 10 pfu/cell 
in ISREC-O1 and SW480 cells. B. MTT assays in the same cell lines. Dotted line, parental virus. Solid line, E1A-HD2 virus. C. 
The change in EC50 calculated from the data in B.
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Burst and xenograft assays Figure 6
Burst and xenograft assays. A. Burst assays showing that the E1A-HD2 viruses vCF212 (derived from vCF22: Tcf-E1A, E1B, 
E2, E4) and vCF192 (derived from vKH1: Tcf-E1A, E1B, E4) have similar burst size to the parental viruses in SW480, Hct116 
and Co115 colon cancer cells and HeLa cells. Error bars: SEM, n = 3. B. Growth curves of subcutaneous SW620 xenografts in 
NMRI nu/nu mice. Mice received 1011 particles of vKH1, vCF192 or buffer control i.v. on day 0. Error bars: SEM, n = 6.
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lines in vitro. The fusion protein binds to β-catenin,
recruits it to the nucleus and increases the transcriptional
activity of Tcf-regulated promoters. Despite this evidence
for increased activity in vitro, the fusion protein does not
increase the activity of the viruses in an SW620 xenograft
model in vivo.
We and others have reported that E1A can inhibit Tcf-
dependent transcription through sequestration of p300
[12,24,25]. This is not a desirable property in a Tcf-regu-
lated adenovirus because it interferes with strong activa-
tion of the promoters. We previously attempted to
circumvent this problem by mutating the p300 binding
site in E1A, but the resulting viruses were 10-fold attenu-
ated relative to matched viruses with wild type E1A, indi-
cating that E1A-binding to p300 is more important for
other functions of the virus than inhibition of cellular Tcf-
dependent transcription [12]. We report here an alterna-
tive solution to the problem: fusion of HD2 to the C-ter-
minus of E1A relieves the repression of Tcf-regulated
transcription by E1A. Unlike mutation of the p300 bind-
ing site, the resulting viruses have increased activity. The
relief of transcriptional repression by E1A can not be
explained by concurrent transcriptional activation
through pygopus, unless HD2 domains can form mixed
oligomers that allow simultaneous recruitment of E1A-
HD2 and BCL9. An alternative explanation is that 12S
E1A-HD2 recruits E1A-p300 complexes which retain
some p300 functions that contribute positively to tran-
scriptional activation [26].
Low Tcf activity has been reported in about half of the
colon cancer cell lines where it has been tested, despite the
presence of confirmed mutations in either APC or β-cat-
enin [23]. One reason for the low activity is thought to be
inadequate localization of β-catenin to the nucleus. β-cat-
enin exists in three pools, a stable pool bound to E-cad-
herin in adherens junctions, and unstable cytosolic and
nuclear pools. Loss of E-cadherin has been reported to
increase Tcf activity in some systems [27], but the major
factor responsible for the Tcf activation in tumors is the
stabilization of β-catenin, which increases the size of the
cytosolic and nuclear pools of β-catenin. The relative
abundance of the two pools depends on the balance of
import and export of β-catenin from the nucleus [28]. β-
catenin itself lacks import or export signals, but can inter-
act directly with nuclear pore proteins [29] and may be
imported in a complex with BCL9 [30]. APC has been
shown to mediate export of β-catenin through clusters of
nuclear export signals (NES) at the N-terminus and in the
central region preceding the axin binding site [31,32].
APC mutations in tumors predominantly truncate the
protein before the axin binding site, which is important
for stabilization of β-catenin, but occasionally retain the
central export signals. Cell lines like HT29, which contain
APC mutants that retain the ability to export β-catenin,
tend to have lower Tcf activity than cell lines like SW480,
which truncate APC before the central NES cluster [23].
Retention of the central NES cluster is rare when APC is
mutant, but retention of wild type APC is common in
tumors from patients with HNPCC. Consistent with the
ability of APC to export β-catenin from the nucleus,
silencing of APC expression by RNAi has been shown to
increase the Tcf activity of an HNPCC cell line with
mutant β-catenin and wild type APC [33]. Taken together,
these data suggest that promoting nuclear localization of
β-catenin by fusion of HD2 to E1A, which has a strong
NLS, might increase the activity of the E1A-HD2 viruses. It
is important to note, however, that there are many cell
lines where low Tcf activity is at best only partially
explained by differences in nuclear import and export of
β-catenin. Co-expression of BCL9 and pygopus promoted
nuclear localization of β-catenin in SW480 but failed to
do so in 293T, HT29 and Hct116 cells [30], and silencing
of APC by RNAi only leads to Tcf activation in a minority
of cases (CF and RI, unpublished data). There are certainly
many other factors which can interfere with β-catenin
transport or Tcf activity, such as tyrosine phosphorylation
or binding to ICAT or chibby [34-37].
The E1A-HD2 gene is expressed from a Tcf-regulated pro-
moter in the HD2 virus. This should result in positive
feedback regulation of E1A-HD2 expression. E1A-HD2
expression by the new virus was clearly higher than E1A
expression by the parental virus in HT29 cells at 48 hours,
but the difference at 24 hours in HT29 and the other colon
cancer cell lines was small. There was a bigger effect on
expression of the E2 and E4 proteins, suggesting that
recruitment of E1A to the other early promoters is more
important than positive feedback of E1A on its own
expression.
The E1A-HD2 virus was more active in CPE assays in
SW480, ISRECO1 and HT29 but not Hct116 cells. The rea-
son for the lack of effect on CPE in Hct116 is unknown.
Hct116 cells have a mutation in p300, which may limit
the ability of E1A-HD2 to activate the viral promoters
[38], although it seems unlikely that this is the only expla-
nation because DBP was expressed better by the E1A-HD2
virus than the parental Tcf-regulated virus (Figure 4A).
Hct116 cells are deficient in mismatch repair and conse-
quently contain point and insertion/deletion mutations
scattered throughout the genome, some of which may
limit the activity of the virus downstream of early viral
promoter activation. To test the fusion strategy in vivo we
made a simpler version of the virus (vCF192) with a wild
type E2 promoter because the virus with Tcf sites in all the
early promoters is too attenuated to be useful in vivo. The
resulting E1A-HD2 virus was indistinguishable from the
parental virus in the xenograft model we tested. It is pos-BMC Cancer 2006, 6:236 http://www.biomedcentral.com/1471-2407/6/236
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sible that xenografted cell lines with lower Tcf activity
would show a preference for the E1A-HD2 virus in vivo,
but this was not pursued because of the relatively small
difference in activity of the E1A-HD2 viruses in vitro.
Since the block in cells with low Tcf activity is refractory to
increases in the nuclear β-catenin pool, it seems likely that
a more fruitful oncolytic strategy would be to make
viruses that target steps downstream of β-catenin.
In principle, our fusion protein strategy could be used to
increase the activity of all types of oncolytic viruses, with-
out loss of selectivity for tumor cells. The general argu-
ment for an adenovirus would be to place binding sites for
a protein Y in the early viral promoters and fuse E1A to a
protein X that can bind to Y. This would trigger a positive
feedback loop in cells with Y at the viral promoters.
Tumor selectivity depends on the fusion protein being
unable to activate transcription in a normal cell, which
means that Y should not be present at the viral promoters
in these cells. We show three examples of pathways that
could be targeted using this approach in Figure 7. In each
case, the critical change is that the amount of Y at the pro-
moter is greater in tumor cells, either because of onco-
genic mutations or tumor hypoxia.
Conclusion
Fusion of the BCL9 HD2 domain to E1A increased the
nuclear pool of β-catenin, consistent with the presence of
a strong NLS in E1A, but this resulted in only small
changes in the activity of the virus. This indicates that the
amount of β-catenin in the nucleus is not limiting for viral
activity in colon cancer cell lines with low Tcf activity, and
suggests that factors downstream of β-catenin are limiting
for viral toxicity in these cells.
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